MARINUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.405 USD | -1.06% |
|
+1.81% | -87.07% |
| Apr. 17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
| Apr. 16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 177.7 | 434.2 | 436.8 | 197.5 | 593.2 | 77.17 | - | - |
| Enterprise Value (EV) 1 | 177.7 | 294.3 | 354.7 | 58.82 | 670.5 | 77.17 | 77.17 | 77.17 |
| P/E ratio | -2.18 x | -4.36 x | -4.42 x | -7.8 x | -4.13 x | -0.63 x | -1.07 x | -4.11 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 253 x | 28.5 x | 7.75 x | 19.1 x | 1.88 x | 1.24 x | 0.58 x |
| EV / Revenue | - | 253 x | 28.5 x | 7.75 x | 19.1 x | 1.88 x | 1.24 x | 0.58 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -3.63 x | -7.13 x | -7.72 x | -1.72 x | -5.02 x | -1.33 x | -1.68 x | 2.14 x |
| FCF Yield | -27.6% | -14% | -13% | -58.1% | -19.9% | -75.2% | -59.6% | 46.7% |
| Price to Book | - | 3.25 x | 8.14 x | 1.34 x | 35.4 x | - | - | - |
| Nbr of stocks (in thousands) | 20,568 | 35,594 | 36,766 | 49,618 | 54,574 | 54,924 | - | - |
| Reference price 2 | 8.640 | 12.20 | 11.88 | 3.980 | 10.87 | 1.405 | 1.405 | 1.405 |
| Announcement Date | 3/16/20 | 3/9/21 | 3/21/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1.718 | 15.34 | 25.48 | 30.99 | 41.06 | 62.09 | 133.2 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -54.42 | -67.94 | -95.45 | -112.8 | -131.5 | -125.5 | -86.12 | -30.74 |
| Operating Margin | - | -3,954.42% | -622.05% | -442.69% | -424.3% | -305.56% | -138.71% | -23.07% |
| Earnings before Tax (EBT) 1 | -54.12 | -67.48 | -98.78 | -16.43 | -142.9 | -136 | -99.34 | -35.94 |
| Net income 1 | -54.12 | -76.36 | -98.78 | -19.82 | -141.4 | -133.3 | -93.72 | -29.59 |
| Net margin | - | -4,444.41% | -643.7% | -77.78% | -456.31% | -324.6% | -150.95% | -22.2% |
| EPS 2 | -3.960 | -2.800 | -2.690 | -0.5100 | -2.630 | -2.231 | -1.317 | -0.3420 |
| Free Cash Flow 1 | -49.02 | -60.91 | -56.57 | -114.7 | -118.1 | -58 | -46 | 36 |
| FCF margin | - | -3,545.52% | -368.67% | -450.04% | -381.17% | -141.26% | -74.09% | 27.02% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/9/21 | 3/21/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10.11 | 1.52 | 14.19 | 1.79 | 2.34 | 7.162 | 10.38 | 6.081 | 7.338 | 7.19 | 9.125 | 9.587 | 10.5 | 11.86 | 11.17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -19.17 | -27.12 | -16.71 | -36.77 | -30.1 | -29.21 | -32.96 | -31.44 | -31.65 | -35.44 | -36.21 | -32.85 | -29.24 | -26.79 | -26.52 |
| Operating Margin | -189.53% | -1,783.95% | -117.8% | -2,053.97% | -1,286.28% | -407.87% | -317.56% | -517% | -431.26% | -492.87% | -396.85% | -342.62% | -278.55% | -225.89% | -237.36% |
| Earnings before Tax (EBT) 1 | -19.51 | -28.3 | -19.36 | -39.43 | 75.04 | -32.68 | -34.73 | -33.47 | -32.97 | -41.77 | -37.45 | -35.74 | -32.26 | -30.1 | -28.66 |
| Net income 1 | -19.51 | -28.3 | -19.36 | -39.43 | 71.63 | -34.31 | -34.73 | -31.93 | -32.97 | -41.77 | -36.87 | -35.38 | -31.24 | -29.07 | -27.36 |
| Net margin | -192.87% | -1,862.17% | -136.48% | -2,202.96% | 3,061.28% | -479.08% | -334.59% | -525.14% | -449.33% | -580.93% | -404.04% | -369.09% | -297.62% | -245.11% | -244.91% |
| EPS 2 | -0.5300 | -0.7700 | -0.5200 | -1.060 | 1.890 | -0.7600 | -0.6700 | -0.6100 | -0.6100 | -0.7400 | -0.6590 | -0.6040 | -0.5480 | -0.4450 | -0.2925 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/21/22 | 5/12/22 | 8/11/22 | 11/7/22 | 3/9/23 | 5/11/23 | 8/10/23 | 11/7/23 | 3/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | 77.3 | - | - | - |
| Net Cash position | - | 140 | 82.1 | 139 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -49 | -60.9 | -56.6 | -115 | -118 | -58 | -46 | 36 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | 3.750 | 1.460 | 2.970 | 0.3100 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.39 | - | 1.1 | 1.77 | 0.11 | 2 | 2 | 2 |
| Capex / Sales | - | - | 7.14% | 6.96% | 0.35% | 4.87% | 3.22% | 1.5% |
| Announcement Date | 3/16/20 | 3/9/21 | 3/21/22 | 3/9/23 | 3/5/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.405
USD
Average target price
8.778
USD
Spread / Average Target
+524.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.07% | 77.17M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- MRNS Stock
- Financials Marinus Pharmaceuticals, Inc.
